Overall response to anti-IL-5/anti-IL5-Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness
Positive bronchodilator responsiveness (BDR) (change in forced expiratory volume in 1 second [ΔFEV1] ≥ +200 mL and ≥ +12%) after inhalation of a short-acting beta-2 agonist has been an inclusion criterion in licensing trials of anti-interleukin 5/anti-interleukin 5 receptor alpha (anti-IL-5/anti-IL-...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 July 2022
|
| In: |
The journal of allergy and clinical immunology. In practice
Year: 2022, Volume: 10, Issue: 12, Pages: 3174-3183 |
| ISSN: | 2213-2201 |
| DOI: | 10.1016/j.jaip.2022.07.007 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jaip.2022.07.007 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2213219822007061 |
| Author Notes: | Carlo Mümmler, Hendrik Suhling, Julia Walter, Nikolaus Kneidinger, Roland Buhl, Moritz Z. Kayser, Nora Drick, Jürgen Behr, Tobias Welte, Stephanie Korn, Katrin Milger |
| Summary: | Positive bronchodilator responsiveness (BDR) (change in forced expiratory volume in 1 second [ΔFEV1] ≥ +200 mL and ≥ +12%) after inhalation of a short-acting beta-2 agonist has been an inclusion criterion in licensing trials of anti-interleukin 5/anti-interleukin 5 receptor alpha (anti-IL-5/anti-IL-5Rα) biologics in severe asthma. However, in clinical practice, patients with severe uncontrolled asthma frequently show a negative BDR. To investigate whether the response to anti-IL5/anti-IL5Rα therapies differs between patients with positive and negative BDR at baseline. |
|---|---|
| Item Description: | Dateiversion vom 7. Dezember 2022 Gesehen am 07.02.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2213-2201 |
| DOI: | 10.1016/j.jaip.2022.07.007 |